Abstract
To assess the comparative health and budget impact of low-dose dabigatran indicated for non-valvular atrial fibrillation (AF) population versus reduced doses of apixaban and rivaroxaban in the Netherlands.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have